Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer
Journal of Oncology · 16.02.2023 · 2023 · 1-10
DOI: 10.1155/2023/7335456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 16.02.2023. Verfasst von Jing He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, Nanjing, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu Province's Key Provincial Talents Program.
Abstract (Originalsprache)
In recent years, microRNAs (miRNAs) derived from exosomes have been attracting attention as novel clinical biomarkers in a variety of cancers. In this study, plasma samples from 60 gastric cancer (GC) patients and 63 healthy individuals were collected, and the exosomal microRNAs (ex-miRNAs) were isolated. We determined the specific ex-miRNAs through miRNA microarray and a database of differentially expressed miRNAs called dbDEMC. Then, the expression levels of exosomal miR-31, miR-192, and miR-375 were analyzed by quantitative polymerase chain reaction (qRT-PCR). Compared to the matched controls, exosomal miR-31, miR-375, and miR-192 were significantly upregulated in GC patients. Also, they were found to be associated with gender, with miR-192 being significantly upregulated in male GC patients. Kaplan–Meier analysis indicated that high expressions of exosomal miR-31, miR-375, and miR-192 were positively correlated with poor clinical outcomes of GC patients. Cox univariate and multivariate analysis found that ex-miR-375 expression and TNM stage were independent prognostic factors of overall survival (OS). Our findings revealed that exosomal miR-31, miR-192, and miR-375 might serve as noninvasive, sensitive, and specific biomarkers for the diagnosis and prognosis of GC patients.
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, Nanjing, China.
- Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, Nanjing, China.
ORCID-Profile: Xin Zhou, Zhuqing Rao, Wen Gao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Jiangsu Province's Key Provincial Talents Program
- 333 High Class Talented Man Project
- Six Talent Peaks Project in Jiangsu Province
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
Zitieren
APA
He, J., Wu, J., Dong, S., Xu, J., Wang, J., Zhou, X., Rao, Z., & Gao, W. (2023). Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer. Journal of Oncology, 2023, 1-10. https://doi.org/10.1155/2023/7335456
Vancouver
He J, Wu J, Dong S, Xu J, Wang J, Zhou X, et al. Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer. Journal of Oncology. 2023;2023:1-10. doi:10.1155/2023/7335456
BibTeX
@article{He2023,
author = {He, Jing and Wu, Jing and Dong, Shiyang and Xu, Jing and Wang, Jian and Zhou, Xin and Rao, Zhuqing and Gao, Wen},
title = {Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer},
journal = {Journal of Oncology},
year = {2023},
volume = {2023},
pages = {1--10},
doi = {10.1155/2023/7335456}
}
EUVIMED